These experiments will assess the effects of PROTACs on FAT10 degradation, β-catenin levels, and the severity of renal fibrosis (such as the expression of α-SMA and collagen I), while also evaluating the renal targeting ability and safety of the PROTACs [21,58]. The gene discussed is ACTA1; the disease is renal fibrosis.